Abstract:
Disclosed is a method of preventing, treating or inhibiting bacterial infections. The method comprises administering at least one of the compounds disclosed herein. Also disclosed are methods of increasing acidity of bacterial phagosomes to inhibit bacterial growth, methods of increasing mitochondrial reactive oxygen species (mROS) generation to inhibit bacterial growth in a cell, pharmaceutical compositions and uses thereof.
Abstract:
There is provided a genetically modified cell wherein at least one gene has been deleted from the cell and the gene is selected from the group consisting of p50, p52, p65, c-Rel, and RelB. Also disclosed are methods of identifying a target for treating acute myeloid leukemia (AML) in a subject, methods of treating acute myeloid leukemia (AML) in a subject in need thereof, comprising inhibiting the activity of an NF-KB pathway. Also provided is an ATP13A2 inhibiting agent for use in therapy or medicine, for use in treating AML, and in the manufacture of a medicament for treating AML.
Abstract:
Disclosed is a method of preventing, treating or inhibiting bacterial infections. The method comprises administering at least one of the compounds disclosed herein. Also disclosed are methods of increasing acidity of bacterial phagosomes to inhibit bacterial growth, methods of increasing mitochondrial reactive oxygen species (mROS) generation to inhibit bacterial growth in a cell, pharmaceutical compositions and uses thereof.